Barinthus Biotherapeutics plc Financials
This page shows Barinthus Biotherapeutics plc (BRNS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Barinthus Biotherapeutics plc has an operating margin of -454.1%, meaning the company retains $-454 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -10463.1% the prior year.
Barinthus Biotherapeutics plc's revenue surged 1766.5% year-over-year to $15.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Barinthus Biotherapeutics plc carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.03, Barinthus Biotherapeutics plc holds $8.03 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Barinthus Biotherapeutics plc generated -$28.9M in operating cash flow, capex of $892K consumed most of it, leaving -$29.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Barinthus Biotherapeutics plc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Barinthus Biotherapeutics plc generates $0.47 in operating cash flow (-$28.9M OCF vs -$61.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Barinthus Biotherapeutics plc earns $-1282.5 in operating income for every $1 of interest expense (-$68.0M vs $53K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Barinthus Biotherapeutics plc generated $15.0M in revenue in fiscal year 2024. This represents an increase of 1766.5% from the prior year.
Barinthus Biotherapeutics plc's EBITDA was -$62.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.8% from the prior year.
Barinthus Biotherapeutics plc generated -$29.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 47.0% from the prior year.
Barinthus Biotherapeutics plc reported -$61.1M in net income in fiscal year 2024. This represents an increase of 16.7% from the prior year.
Barinthus Biotherapeutics plc earned $-1.55 per diluted share (EPS) in fiscal year 2024. This represents an increase of 18.8% from the prior year.
Barinthus Biotherapeutics plc held $110.7M in cash against $0 in long-term debt as of fiscal year 2024.
Barinthus Biotherapeutics plc had 40M shares outstanding in fiscal year 2024. This represents an increase of 4.1% from the prior year.
Barinthus Biotherapeutics plc's operating margin was -454.1% in fiscal year 2024, reflecting core business profitability. This is up 10009.0 percentage points from the prior year.
Barinthus Biotherapeutics plc's net profit margin was -408.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 8737.5 percentage points from the prior year.
Barinthus Biotherapeutics plc invested $42.2M in research and development in fiscal year 2024. This represents a decrease of 5.9% from the prior year.
Barinthus Biotherapeutics plc invested $892K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 83.5% from the prior year.
BRNS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | N/A | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.4M-32.2% | $8.0M-4.1% | $8.3M-0.2% | $8.3M-28.7% | $11.7M+4.8% | $11.1M+74.6% | $6.4M-57.9% | $15.1M |
| SG&A Expenses | $5.2M-66.4% | $15.4M+21.7% | $12.6M+313.7% | $3.1M-57.6% | $7.2M+20.1% | $6.0M-56.0% | $13.6M+1316.8% | $961K |
| Operating Income | -$15.1M+35.4% | -$23.3M-13.2% | -$20.6M+11.9% | -$23.4M-27.9% | -$18.3M-8.1% | -$16.9M+15.4% | -$20.0M-24.1% | -$16.1M |
| Interest Expense | $13K+8.3% | $12K-7.7% | $13K+8.3% | $12K0.0% | $12K0.0% | $12K+71.4% | $7K0.0% | $7K |
| Income Tax | -$71K-184.0% | -$25K-13.6% | -$22K-833.3% | $3K+142.9% | -$7K+81.1% | -$37K+95.5% | -$820K-36.0% | -$603K |
| Net Income | -$14.6M+31.0% | -$21.1M-7.5% | -$19.6M+4.3% | -$20.5M-21.3% | -$16.9M-9.3% | -$15.5M+10.4% | -$17.3M-22.9% | -$14.1M |
| EPS (Diluted) | $-0.36+30.8% | $-0.52-6.1% | $-0.49+3.9% | $-0.51-18.6% | $-0.43-7.5% | $-0.40+9.1% | $-0.44-18.9% | $-0.37 |
BRNS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $109.2M-15.7% | $129.6M-8.8% | $142.0M-11.4% | $160.3M-14.1% | $186.7M-6.4% | $199.5M-7.0% | $214.5M-6.7% | $230.0M |
| Current Assets | $86.8M-13.6% | $100.4M-8.6% | $109.9M-12.6% | $125.7M-4.7% | $131.9M-7.9% | $143.1M-8.8% | $156.9M-8.3% | $171.1M |
| Cash & Equivalents | $74.3M-13.9% | $86.3M-13.0% | $99.1M-10.4% | $110.7M-6.0% | $117.8M-9.4% | $130.0M-8.5% | $142.1M-11.4% | $160.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | $0-100.0% | $12.2M0.0% | $12.2M0.0% | $12.2M0.0% | $12.2M |
| Total Liabilities | $24.6M-9.0% | $27.1M+2.6% | $26.4M-12.5% | $30.2M+0.8% | $30.0M+9.1% | $27.5M-0.2% | $27.5M-19.9% | $34.4M |
| Current Liabilities | $10.8M-15.1% | $12.7M+6.3% | $12.0M-23.5% | $15.7M+0.4% | $15.6M+21.5% | $12.8M+1.9% | $12.6M-32.2% | $18.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $84.5M-17.5% | $102.4M-11.4% | $115.5M-11.2% | $130.0M-17.0% | $156.6M-8.9% | $171.8M-8.0% | $186.8M-4.4% | $195.4M |
| Retained Earnings | -$293.0M-5.2% | -$278.4M-8.2% | -$257.3M-8.3% | -$237.7M-13.7% | -$209.0M-8.8% | -$192.1M-8.8% | -$176.6M-10.9% | -$159.3M |
BRNS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.7M+40.8% | -$18.1M-21.5% | -$14.9M-213.9% | $13.1M+209.0% | -$12.0M-1.6% | -$11.8M+39.7% | -$19.6M-75.2% | -$11.2M |
| Capital Expenditures | $0-100.0% | $32K+540.0% | $5K-98.2% | $278K+44.8% | $192K-37.7% | $308K+301.3% | -$153K-525.0% | $36K |
| Free Cash Flow | -$10.7M+40.9% | -$18.1M-21.7% | -$14.9M-216.4% | $12.8M+205.0% | -$12.2M-0.6% | -$12.1M+38.6% | -$19.8M-76.0% | -$11.2M |
| Investing Cash Flow | $451K+1509.4% | -$32K-540.0% | -$5K+98.2% | -$278K-44.8% | -$192K+37.7% | -$308K-301.3% | $153K+525.0% | -$36K |
| Financing Cash Flow | $0 | $0-100.0% | $2K-99.8% | $837K+133.8% | $358K-28.8% | $503K+361.5% | $109K+137.0% | $46K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BRNS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -62.7% | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -54.2% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.3%+3.0pp | -16.3%-2.5pp | -13.8%-1.0pp | -12.8%-3.7pp | -9.1%-1.3pp | -7.8%+0.3pp | -8.1%-1.9pp | -6.1% |
| Current Ratio | 8.04+0.1 | 7.89-1.3 | 9.18+1.1 | 8.03-0.4 | 8.46-2.7 | 11.15-1.3 | 12.45+3.2 | 9.21 |
| Debt-to-Equity | 0.29+0.0 | 0.26+0.0 | 0.230.0 | 0.23+0.0 | 0.19+0.0 | 0.16+0.0 | 0.15-0.0 | 0.18 |
| FCF Margin | N/A | N/A | N/A | -122.3% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Barinthus Biotherapeutics plc's annual revenue?
Barinthus Biotherapeutics plc (BRNS) reported $15.0M in total revenue for fiscal year 2024. This represents a 1766.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Barinthus Biotherapeutics plc's revenue growing?
Barinthus Biotherapeutics plc (BRNS) revenue grew by 1766.5% year-over-year, from $802K to $15.0M in fiscal year 2024.
Is Barinthus Biotherapeutics plc profitable?
No, Barinthus Biotherapeutics plc (BRNS) reported a net income of -$61.1M in fiscal year 2024, with a net profit margin of -408.0%.
What is Barinthus Biotherapeutics plc's earnings per share (EPS)?
Barinthus Biotherapeutics plc (BRNS) reported diluted earnings per share of $-1.55 for fiscal year 2024. This represents a 18.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Barinthus Biotherapeutics plc's EBITDA?
Barinthus Biotherapeutics plc (BRNS) had EBITDA of -$62.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Barinthus Biotherapeutics plc's operating margin?
Barinthus Biotherapeutics plc (BRNS) had an operating margin of -454.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Barinthus Biotherapeutics plc's net profit margin?
Barinthus Biotherapeutics plc (BRNS) had a net profit margin of -408.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Barinthus Biotherapeutics plc's free cash flow?
Barinthus Biotherapeutics plc (BRNS) generated -$29.8M in free cash flow during fiscal year 2024. This represents a 47.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Barinthus Biotherapeutics plc's operating cash flow?
Barinthus Biotherapeutics plc (BRNS) generated -$28.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Barinthus Biotherapeutics plc's total assets?
Barinthus Biotherapeutics plc (BRNS) had $160.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Barinthus Biotherapeutics plc's capital expenditures?
Barinthus Biotherapeutics plc (BRNS) invested $892K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Barinthus Biotherapeutics plc spend on research and development?
Barinthus Biotherapeutics plc (BRNS) invested $42.2M in research and development during fiscal year 2024.
How many shares does Barinthus Biotherapeutics plc have outstanding?
Barinthus Biotherapeutics plc (BRNS) had 40M shares outstanding as of fiscal year 2024.
What is Barinthus Biotherapeutics plc's current ratio?
Barinthus Biotherapeutics plc (BRNS) had a current ratio of 8.03 as of fiscal year 2024, which is generally considered healthy.
What is Barinthus Biotherapeutics plc's debt-to-equity ratio?
Barinthus Biotherapeutics plc (BRNS) had a debt-to-equity ratio of 0.23 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Barinthus Biotherapeutics plc's return on assets (ROA)?
Barinthus Biotherapeutics plc (BRNS) had a return on assets of -38.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Barinthus Biotherapeutics plc's cash runway?
Based on fiscal year 2024 data, Barinthus Biotherapeutics plc (BRNS) had $110.7M in cash against an annual operating cash burn of $28.9M. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Barinthus Biotherapeutics plc's Piotroski F-Score?
Barinthus Biotherapeutics plc (BRNS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Barinthus Biotherapeutics plc's earnings high quality?
Barinthus Biotherapeutics plc (BRNS) has an earnings quality ratio of 0.47x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Barinthus Biotherapeutics plc cover its interest payments?
Barinthus Biotherapeutics plc (BRNS) has an interest coverage ratio of -1282.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Barinthus Biotherapeutics plc?
Barinthus Biotherapeutics plc (BRNS) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.